Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

被引：0
|
作者：
Passalacqua, R.
Buzio, C.
Buti, S.
Labianca, R.
Porta, C.
Boni, C.
Rondini, E.
Camisa, R.
Sabbatini, R.
Artioli, F.
Caminiti, C.
机构：
[1] Ist Ospitalieri, Cremona, Italy
[2] Univ Parma, Parma, Italy
[3] Bergamo Hosp, Bergamo, Italy
[4] Policlin San Matteo, Pavia, Italy
[5] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[6] Univ Hosp, Parma, Italy
[7] Univ Hosp, Modena, Italy
[8] Hosp Carpi, Carpi, MO, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5028
引用
收藏
页数：1
相关论文
共 42 条
  • [41] A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914
    Shimoyama, Ryo
    Omori, Shota
    Nomura, Shogo
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Harada, Hideyuki
    Ishikura, Satoshi
    Mizutani, Tomonori
    Ando, Masahiko
    Kataoka, Tomoko
    Fukuda, Haruhiko
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 836 - 841
  • [42] A multi-institutional randomized phase III trial comparing postoperative radiotherapy to observation after adjuvant chemotherapy in patients with pathological N2 Stage III non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1916 (J-PORT study)
    Shimoyama, Ryo
    Nakagawa, Kazuo
    Ishikura, Satoshi
    Wakabayashi, Masashi
    Sasaki, Tomonari
    Yoshioka, Hiroshige
    Hashimoto, Tadayoshi
    Kataoka, Tomoko
    Fukuda, Haruhiko
    Watanabe, Shun-Ichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 999 - 1003
12345